Funder
National Research Foundation
Publisher
Springer Science and Business Media LLC
Subject
Organic Chemistry,Drug Discovery,Molecular Medicine
Reference170 articles.
1. Agilent Technologies (2020) Agilent receives expanded FDA approval for PD-L1 IHC 22C3 pharmDx in triple-negative breast cancer. https://www.agilent.com/about/newsroom/presrel/2020/13nov-ca20029.html. Accessed 13 Nov 2020
2. Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL (2021) Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol 39:2443–2451. https://doi.org/10.1200/JCO.20.02923
3. Ambrogi F, Fornili M, Boracchi P, Trerotola M, Relli V, Simeone P, La Sorda R, Lattanzio R, Querzoli P, Pedriali M, Piantelli M, Biganzoli E, Alberti S (2014) Trop-2 is a determinant of breast cancer survival. PLoS ONE 9:e96993. https://doi.org/10.1371/journal.pone.0096993
4. Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Papai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D, and Group S-S (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380:1929–1940. https://doi.org/10.1056/NEJMoa1813904
5. Andre F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Papai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS (2021) Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 32:208–217. https://doi.org/10.1016/j.annonc.2020.11.011
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献